The company has created the Find It assay platform, which detects mutations in solid tumor tissue, including single-base substitutions, small deletions, and insertions. It evaluates the mutation status of tumor DNA in 30 known cancer-associated genes simultaneously, covering various types of solid tumor cancers. Canexia Health also offers the Follow It assay for cases where biopsy is unavailable or tissue quality is poor, and the Fusion assay for isolating and analyzing relevant fusions. With a network of over 20 hospitals and reference labs worldwide, the company combines AI expertise with advanced molecular biopsy solutions to provide oncologists with clinical decision support and cost-effective cancer testing options for patients. Their actionable molecular tests improve patient diagnosis and treatment options, leading to better outcomes.